Marrone Bio Innovations, Inc. (MBII)

ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions completes merger with Madrone Bio, creating a global leader in sustainable agricultural solutions

RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI's stockholders approved the adoption of the Merger Agreement and approved on a non-binding advisory basis certain executive compensation that may be paid or become payable in connection with the merger contemplated by the Merger Agreement. The final voting results for each proposal voted on at the special meeting will be set forth in a Form 8-K filed by MBI with the U.S. Securities and Exchange Commission.

Marrone Bio (MBII) witnessed increased sales of row crop products in the first quarter, offset by lower sales into specialty crop markets.

Marrone Bio Innovations, Inc. (NASDAQ:MBII ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Kevin Helash – Chief Executive Officer Linda Moore – Chief Legal Officer LaDon Johnson – Interim Chief Financial Officer Matti Tiainen – Senior Vice President International Sales Kamal El Mernissi – Senior Director of Product & Marketing Conference Call Participants Dmitry Silversteyn – Water Tower Research Operator Good afternoon ladies and gentlemen, and welcome to the First Quarter 2022 Earnings conference call. At this time all participants are in a listen-only mode.

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -300% and 8.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include:

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Marrone Bio Innovations, Inc. (NasdaqCM: MBII) to Bioceres Crop Solutions Corp. (NasdaqGS: BIOX). Under the terms of the proposed transaction, shareholders of Marrone will receive only 0.088 shares of Bioceres for each share of Marrone that they own. If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (dk@kclasslaw.com), or visit https://kclasslaw.com/cases/ma/nasdaqcm-mbii/ to learn more. Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marrone Bio Innovations, Inc. (NasdaqCM: MBII) to Bioceres Crop Solutions Corp. (NasdaqGS: BIOX). Under the terms of the proposed transaction, shareholders of Marrone will receive only 0.088 shares of Bioceres for each share of Marrone that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-mbii/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0% and 3.85%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2021 Results - Earnings Call Transcript

RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include:

Company poised for continued growth in a $6+ billion market¹ Company poised for continued growth in a $6+ billion market¹

Farming & Agriculture Penny Stocks To Watch Right Now. The post Best Penny Stocks To Buy?

Wilmington, Delaware--(Newsfile Corp. - March 21, 2022) - Rigrodsky Law, P.A. is investigating Marrone Bio Innovations, Inc. ("Marrone") (NASDAQ: MBII) regarding possible breaches of fiduciary duties and other violations of law related to Marrone's agreement to be acquired by Bioceres Crop Solutions Corp. ("Bioceres") (NASDAQ: BIOX). Under the terms of the agreement, Marrone's shareholders will receive 0.088 shares of Bioceres common stock for each share of Marrone common stock they own.To learn more about this...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marrone Bio Innovations, Inc. (NasdaqCM: MBII) to Bioceres Crop Solutions Corp. (NasdaqGS: BIOX). Under the terms of the proposed transaction, shareholders of Marrone will receive only 0.088 shares of Bioceres for each share of Marrone that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-mbii/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Today, a big merger announcement has prompted investors to pile into Marrone Bio Innovations and MBII stock, as this stock surges 50%. The post Why Is Marrone Bio Innovations (MBII) Stock Up Today?